4D Path Inc. news
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development.
4D Path’s patented precision oncology platform unveils previously hidden data to inst
4D Path applies universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints. Its system runs on modern cloud components that enable dynamic scaling and batch processing, allowing 4D to optimize run times and deliver rapid results. Utilizing Microsoft Azure`s cloud technology, 4D Path has built stable and secure environments to host both research and regulated workflows fo
4D Path recently had the honor of including two publications in the virtual curriculum at the 2022 ASCO Annual Meeting. The publications addressed that the majority of druggable targets that drive oncogenic vulnerability are not expressed in a uniform or homogeneous manner throughout tumor tissue. Thus, intratumoral heterogeneity, as observed among the cells of an individual tumor, poses a major challenge in targeted therapy selec
PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast
Transitioning from his role as a 4D Path advisory board member, world-renowned cancer oncologist, health consultant, and entrepreneur Dr. Teich will now serve as 4D Path’s Chief Global Strategist. Dr. Teich’s expertise in facilitating clinical research and supporting innovative, evidence-based health technologies will support 4D Path’s efforts to bring more readily accessible and affordable care to different countries and their diverse systems, realities, and providers. Prio